{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:47:07Z","timestamp":1787071627967,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alopecia areata (AA) is an autoimmune condition marked by non-scarring hair loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Method:<\/jats:title>\n                    <jats:p>In this prospective observational study, we enrolled 50 pediatric patients with moderate-to-severe alopecia areata. Participants received oral tofacitinib for 24 weeks. Clinical efficacy was assessed using the Severity of Alopecia Tool (SALT) score. Secondary outcomes included time to hair regrowth, patient\/parent satisfaction, and Paediatric Quality of Life Inventory (PedsQL) scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>\n                      Forty-five participants completed the 24-week study. A significant decrease in SALT score from baseline (mean 66.2 \u00b1 8.1) to week 24 (mean 25.7 \u00b1 9.2) was observed (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Complete or near-complete hair regrowth was achieved in 42.2% of patients, with partial regrowth in 37.8%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Tofacitinib demonstrated a favorable risk\u2013benefit profile for treating moderate-to-severe pediatric alopecia areata over 24 weeks. These findings support the potential of JAK inhibitors as a therapeutic option in children with recalcitrant disease, although long-term safety and relapse rates warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_617_25","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T03:00:17Z","timestamp":1747364417000},"page":"S2500-S2502","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study"],"prefix":"10.4103","volume":"17","author":[{"given":"Farah","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, AIIMS, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, Gajra Raja Medical College, Gwalior, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekhar","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, CIMS, Chhindwara, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Dandotiya","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, CIMS, Chhindwara, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"R1-20250930","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250930","first-page":"1531","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"11","author":"Petukhova","year":"2020","journal-title":"Nat Commun"},{"key":"R3-20250930","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaad.2021.04.077","article-title":"Treatment of pediatric alopecia areata:A systematic review","volume":"86","author":"Barton","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250930","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20250930","first-page":"1763","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis:Results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1)","volume":"384","author":"Papp","year":"2018","journal-title":"Lancet"},{"key":"R6-20250930","doi-asserted-by":"crossref","first-page":"13418","DOI":"10.2340\/actadv.v103.13418","article-title":"Effectiveness of tofacitinib in pre-adolescent alopecia areata:A retrospective case series and literature review","volume":"103","author":"Huang","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"R7-20250930","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5021\/ad.2019.31.2.231","article-title":"Long-term prognosis of alopecia areata in children and adolescents","volume":"31","author":"Jang","year":"2019","journal-title":"Ann Dermatol"},{"key":"R8-20250930","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata:An appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_617_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:49:49Z","timestamp":1787068189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_617_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":8,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_617_25","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"2025-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}